Cyclo Therapeutics Inc (CYTH)

[octagramt]

$1.70, sounds good, but anyways, how do you know it's CTD that will be used to supply the cyclodextrin and not say, Wacker Biochem Corporation, which is located in Michigan?

Perhaps my understanding of the whole situation is wrong, and I invite you to please correct it or fill in the gaps if there are any. To my understanding it's not an open market on orphan drugs and only one company will be used to distrubute the product to the consumers needing it for 7 years (this being done as an incentive for companies to do R&D for the orphan disease since there is only a small market for orphan diseases). CTD is not a pharmaceutical company, but a company that manufactures Trappsol which is their cyclodextrin, hence they won't actually be selling to the consumer but instead supplying cyclodextrin to the medical company that will actually be developing the drug.

So based on my understanding which I just present, and which I ask that you please correct if there's any mistakes in it, my question is, how do we know which company is awarded rights to distrubute the new potential drug, and how do know that it would be CTD that would be the supplier to that company?